Clinical Research Papers:
Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke
PDF | HTML | How to cite
Metrics: PDF 1092 views | HTML 2085 views | ?
Han Dong1,5, Zhi-Hao Wang1, Na Zhang2, Si-Da Liu3, Jian-Jun Zhao4,* and Song-Yan Liu5,*
1 Department of Geriatric Medicine, The First Affiliated Hospital of Jilin University, Changchun, China
2 Department of Electrical Diagnosis, The General Hospital of Fourth Hospital of Jilin University, Changchun, China
3 Department of Thoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 Department of Neurology, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China
5 Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China
* These authors have contributted equally to this study
Song-Yan Liu, email:
Keywords: ischemic stroke, Galectin-3, prognosis
Received: February 03, 2017 Accepted: May 01, 2017 Published: May 25, 2017
Aim: To study the diagnostic and prognostic role of serum galectin-1 (Gal-1) and -3 (Gal-3) in acute ischemic stroke (AIS) patients.
Methods: We enrolled 233 patients with first-ever acute ischemic stroke and 252 healthy controls in this study. The AIS severity was evaluated by National Institutes of Health Stroke Scale (NIHSS) scores. The serum Gal-1 and -3 levels were determined. All patients were followed for 1 years and the functional outcome were evaluated by modified Rankin Scale (mRS) scores.
Results: We found that AIS patients had higher serum Gal-1 and -3 levels than controls. The serum Gal-3 level was closely associated with the AIS severity indicated by NHSS and infarction volume. Serum Gal-3 levels were significantly higher in patients with a poor outcome indicated by mRS scores than those in patients with a good outcome. In contrast, the serum Gal-1 is not associated with the severity and outcome of acute AIS patients. Our in vitro studies show that Gal-3 knockdown with siRNA dramatically increased the culture neuron cell viability and reduced apoptosis under oxygen glucose deprivation treatment. Meanwhile, the pro-inflammatory cytokine expression decreased with the inhibition of Gal-3.
Conclusion: Our finding provides a novel biological marker, serum Gal-3, for monitor of acute AIS patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.